Neovacs Files Patent for New Lipids in RNA Delivery
French biotech company Neovacs announced on Tuesday the filing of a patent application protecting a new family of proprietary lipids, co-developed with the UTCBS laboratory. This innovation aims to strengthen its positioning in the therapeutic RNA delivery technologies, a critical segment of the expanding RNA market.
A Collaboration Formalized by a Patent Filing
Neovacs has filed a patent application covering new lipids co-developed with the Chemical and Biological Technologies for Health Unit (UTCBS, CNRS/UPC/INSERM), led by Dr. Nathalie Mignet. The collaboration between the two entities began in May 2024 and focuses on the design of lipids for mRNA formulation, to induce an antibody response against overexpressed cytokines in chronic inflammatory diseases.
The application is currently under review by the relevant offices and its issuance remains subject to standard evaluation procedures.
Lipids as a Differentiation Lever in the RNA Ecosystem
According to Hugo Brugière, CEO of Neovacs, this filing 'marks an important step in the group's value creation strategy.' Delivery technologies are a critical link in the global RNA market, which is experiencing strong growth driven by new applications in oncology, rare diseases, and autoimmune diseases. This new family of proprietary lipids could pave the way for the establishment of a platform intended to be exploited in internal programs as well as in the context of external partnerships, offering a way around existing intellectual property barriers in this field.
Lipid nanoparticles are the reference technology for the administration of nucleic acids, generating increasing interest from industrial players in accessing innovative solutions.
